<?xml version='1.0' encoding='utf-8'?>
<document id="22625877"><sentence text="Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone."><entity charOffset="74-85" id="DDI-PubMed.22625877.s1.e0" text="gemfibrozil" /><entity charOffset="90-102" id="DDI-PubMed.22625877.s1.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.22625877.s1.e0" e2="DDI-PubMed.22625877.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22625877.s1.e0" e2="DDI-PubMed.22625877.s1.e1" /></sentence><sentence text="The objective of this study was to determine the extent to which the CYP2C8*3 allele influences pharmacokinetic variability in the drug-drug interaction between gemfibrozil (CYP2C8 inhibitor) and pioglitazone (CYP2C8 substrate)"><entity charOffset="196-208" id="DDI-PubMed.22625877.s2.e0" text="pioglitazone" /></sentence><sentence text="" /><sentence text="In this randomized, two phase crossover study, 30 healthy Caucasian subjects were enrolled based on CYP2C8*3 genotype (n = 15, CYP2C8*1/*1; n = 15, CYP2C8*3 carriers)" /><sentence text=" Subjects received a single 15 mg dose of pioglitazone or gemfibrozil 600 mg every 12 h for 4 days with a single 15 mg dose of pioglitazone administered on the morning of day 3"><entity charOffset="42-54" id="DDI-PubMed.22625877.s5.e0" text="pioglitazone" /><entity charOffset="58-69" id="DDI-PubMed.22625877.s5.e1" text="gemfibrozil" /><entity charOffset="127-139" id="DDI-PubMed.22625877.s5.e2" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.22625877.s5.e0" e2="DDI-PubMed.22625877.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22625877.s5.e0" e2="DDI-PubMed.22625877.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22625877.s5.e0" e2="DDI-PubMed.22625877.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22625877.s5.e1" e2="DDI-PubMed.22625877.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22625877.s5.e1" e2="DDI-PubMed.22625877.s5.e2" /></sentence><sentence text=" A 48 h pharmacokinetic study followed each pioglitazone dose and the study phases were separated by a 14 day washout period"><entity charOffset="44-56" id="DDI-PubMed.22625877.s6.e0" text="pioglitazone" /></sentence><sentence text="" /><sentence text="Gemfibrozil significantly increased mean pioglitazone AUC(0,∞) by 4"><entity charOffset="0-11" id="DDI-PubMed.22625877.s8.e0" text="Gemfibrozil" /></sentence><sentence text="3-fold (P &lt; 0" /><sentence text="001) and there was interindividual variability in the magnitude of this interaction (range, 1" /><sentence text="8- to 12" /><sentence text="1-fold)" /><sentence text=" When pioglitazone was administered alone, the mean AUC(0,∞) was 29"><entity charOffset="6-18" id="DDI-PubMed.22625877.s13.e0" text="pioglitazone" /></sentence><sentence text="7% lower (P = 0" /><sentence text="01) in CYP2C8*3 carriers compared with CYP2C8*1 homozygotes" /><sentence text=" The relative change in pioglitazone plasma exposure following gemfibrozil administration was significantly influenced by CYP2C8 genotype"><entity charOffset="24-36" id="DDI-PubMed.22625877.s16.e0" text="pioglitazone" /><entity charOffset="63-74" id="DDI-PubMed.22625877.s16.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.22625877.s16.e0" e2="DDI-PubMed.22625877.s16.e0" /><pair ddi="false" e1="DDI-PubMed.22625877.s16.e0" e2="DDI-PubMed.22625877.s16.e1" /></sentence><sentence text=" Specifically, CYP2C8*3 carriers had a 5" /><sentence text="2-fold mean increase in pioglitazone AUC(0,∞) compared with a 3"><entity charOffset="24-45" id="DDI-PubMed.22625877.s18.e0" text="pioglitazone AUC(0,∞)" /></sentence><sentence text="3-fold mean increase in CYP2C8*1 homozygotes (P = 0" /><sentence text="02)" /><sentence text="" /><sentence text="CYP2C8*3 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction"><entity charOffset="38-50" id="DDI-PubMed.22625877.s22.e0" text="pioglitazone" /><entity charOffset="141-165" id="DDI-PubMed.22625877.s22.e1" text="gemfibrozil-pioglitazone" /><pair ddi="false" e1="DDI-PubMed.22625877.s22.e0" e2="DDI-PubMed.22625877.s22.e0" /><pair ddi="false" e1="DDI-PubMed.22625877.s22.e0" e2="DDI-PubMed.22625877.s22.e1" /></sentence><sentence text=" Additional studies are needed to evaluate the impact of CYP2C8 genetics on the pharmacokinetics of other CYP2C8-mediated drug-drug interactions" /><sentence text="" /></document>